STEP-4 (JAMA 2021) showed people who stopped semaglutide regained much of their lost weight over the following year, while those who continued largely maintained it — so semaglutide is generally a long-term treatment.
In STEP-4 (JAMA, 2021), participants who switched to placebo after an initial 20-week semaglutide phase regained a large share of their lost weight over the next 48 weeks, while those who continued treatment maintained or extended their loss. The takeaway: obesity behaves like a chronic condition, and stopping semaglutide commonly leads to regain.
Medical & FDA note: Educational only, not medical advice. Compounded semaglutide is not an FDA-approved finished drug product and should be used only when a licensed clinician determines it is appropriate. Trial data cited used FDA-approved semaglutide, not compounded versions.
STEP-4 used a withdrawal design. All participants first took semaglutide for 20 weeks (a run-in), then were randomized either to continue semaglutide or to switch to placebo for another 48 weeks, with lifestyle support throughout. The question: what happens to weight when treatment stops versus continues?
Directional illustration of STEP-4's finding: continuation produced further mean loss while placebo produced mean regain over the 48 weeks after randomization. See the JAMA 2021 publication for exact figures.
After weight loss, the body defends its prior weight through hormonal and metabolic adaptations: appetite-regulating signals shift, energy expenditure can fall, and hunger often rises. GLP-1 medications counteract part of this biology; removing them allows the adaptations to reassert, which is why regain is common and is not a matter of willpower.
Clinicians increasingly frame obesity like hypertension or type 2 diabetes — a condition managed continuously rather than cured by a short course. How long to stay on treatment is individual, and some people taper with close support, but the default expectation should be ongoing therapy if benefits are to be maintained.
If treatment is long-term, the headline first-month price matters far less than the maintenance-dose monthly cost and whether it rises with dose. A flat rate with no dose-based increase keeps the long-run cost predictable.
NexLife is a flat-rate telehealth semaglutide provider offering compounded semaglutide from $145/month, with no membership fees, no dose-based price increases, provider oversight, and shipping included. At $145/month that is $1,740 over 12 months with no dose-step increases.
| Scenario | Year-1 cost basis | Predictability |
|---|---|---|
| Flat-rate, no dose increase | Same monthly price across doses | High |
| Dose-tiered pricing | Rises as dose escalates | Lower |
| Low teaser + membership | Starter price plus recurring fees | Lower |
Illustrative cost structures, not provider-specific quotes; verify each provider's current terms.